Black Diamond Therapeutic Analyst Price Targets

Wall Street analyst price targets and consensus rating for Black Diamond Therapeutic (BDTX).

Price Target Range — 10 Quarters

Analyst Consensus — 8 Analysts

7Buy

1Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$12Upside to Avg. PT+548.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 29, 2026	BTIG	Robert Burns	PT Raise	Buy	$10→$11
Mar 17, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$13→$14
Jan 16, 2026	Piper Sandler	Kelsey Goodwin	PT Cut	Overweight	$9→$8
Dec 4, 2025	Guggenheim	Brad Canino	Downgrade	Buy→Neutral	—
Nov 18, 2025	Piper Sandler	Kelsey Goodwin	Assumes	Overweight	$9
Oct 16, 2025	Stifel	Laura Prendergast	Reinstates	Buy	$8
Oct 1, 2025	Freedom Broker	Ilya Zubkov	Initiate	Buy	$6
Sep 4, 2025	Guggenheim	Brad Canino	Initiate	Buy	$8
Aug 11, 2025	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$12→$10
Jul 1, 2025	Raymond James	Sean McCutcheon	Reinstates	Outperform	$11
Mar 18, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$11→$12
Mar 7, 2025	Stifel	Bradley Canino	PT Cut	Buy	$16→$15
Nov 6, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$11
Oct 9, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$11
Oct 8, 2024	Wedbush	Robert Driscoll	Maintained	Outperform	$16
Sep 24, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$11
Sep 23, 2024	Piper Sandler	Joseph Catanzaro	PT Raise	Overweight	$12→$15
Sep 18, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$11
Sep 10, 2024	Wedbush	Robert Driscoll	Maintained	Outperform	$16
Sep 4, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$11

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11

BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14

Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Lowers Price Target to $8

Piper Sandler analyst Kelsey Goodwin maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight and lowers the price target from $9 to $8.

Benzinga Newsdesk

This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Avi Kapoor

PRO
Guggenheim Downgrades Black Diamond Therapeutic to Neutral

Guggenheim analyst Brad Canino downgrades Black Diamond Therapeutic (NASDAQ:BDTX) from Buy to Neutral.

Benzinga Newsdesk

PRO
Piper Sandler Assumes Black Diamond Therapeutic at Overweight, Announces Price Target of $9

Piper Sandler analyst Kelsey Goodwin assumes Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight rating and announces Price Target of $9.

Benzinga Newsdesk

Black Diamond Therapeutics Inc

Black Diamond Therapeutic Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11

PRO
Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14

PRO
Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Lowers Price Target to $8

This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

PRO
Guggenheim Downgrades Black Diamond Therapeutic to Neutral

PRO
Piper Sandler Assumes Black Diamond Therapeutic at Overweight, Announces Price Target of $9

People Also Watch

People Also Watch

Black Diamond Therapeutics Inc

Black Diamond Therapeutic Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11

PROWedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14

PROPiper Sandler Maintains Overweight on Black Diamond Therapeutic, Lowers Price Target to $8

This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

PROGuggenheim Downgrades Black Diamond Therapeutic to Neutral

PROPiper Sandler Assumes Black Diamond Therapeutic at Overweight, Announces Price Target of $9

People Also Watch

People Also Watch

PRO
BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11

PRO
Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14

PRO
Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Lowers Price Target to $8

PRO
Guggenheim Downgrades Black Diamond Therapeutic to Neutral

PRO
Piper Sandler Assumes Black Diamond Therapeutic at Overweight, Announces Price Target of $9